Cargando…

A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer

Fork head box p3 (FOXP3), the specific transcription factors of Tregs, not only in Tregs, but also expressed in cancer cells of certain malignant tumors. The histological positioning of FOXP3 in nonsmall cell lung cancer (NSCLC) and its biological significance are still unclear. This study aims to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jianfei, Li, Zhenzhen, Chen, Jie, Li, Wensheng, Wang, Hongtao, Jiang, Tao, Ma, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771226/ https://www.ncbi.nlm.nih.gov/pubmed/36550816 http://dx.doi.org/10.1097/MD.0000000000032102

Ejemplares similares

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
por: Ding, Lin, et al.
Publicado: (2016)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer
por: Liang, Wenjun, et al.
Publicado: (2016)

Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer
por: Kim, Gun-Jik, et al.
Publicado: (2017)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

(125)I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy
por: Xiang, Zhanwang, et al.
Publicado: (2015)

The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
por: Chen, Yu Jie, et al.
Publicado: (2015)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis
por: Li, Xiuwei, et al.
Publicado: (2020)

Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehensive bioinformatics analysis
por: Zhu, Jie, et al.
Publicado: (2023)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report
por: Wu, Yimin, et al.
Publicado: (2017)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients
por: Wang, Kai, et al.
Publicado: (2015)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Preliminary study on the clinical significance of kinesin Kif18a in nonsmall cell lung cancer: An analysis of 100 cases
por: Guo, Weifeng, et al.
Publicado: (2020)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study
por: Zhao, Tongwei, et al.
Publicado: (2016)

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?
por: Nguyen, Nam P., et al.
Publicado: (2016)

Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer – A retrospective analysis
por: Kong, Pengyu, et al.
Publicado: (2017)

The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis
por: Luo, Hui, et al.
Publicado: (2017)

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016)

CXCL14 and NOS1 expression in specimens from patients with stage I–IIIA nonsmall cell lung cancer after curative resection
por: Ji, Xiaoqin, et al.
Publicado: (2018)

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

The clinical prognostic value of lncRNA FOXP4-AS1 in cancer patients: A meta-analysis and bioinformatics analysis based on TCGA datasets
por: Shu, Qiang, et al.
Publicado: (2022)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study
por: Shen-Tu, Yang, et al.
Publicado: (2017)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma
por: Weng, Jiren, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m8mbcsj72d461c36p9fq4s6ipk